RxDoctor Payments Data

Jennifer Wittwer, MD

Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1629457577

Payments from drug & device makers

$2,400in general payments, 2019–2025

Across 61 payments — averaging $39.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$441
  • Dexcom, Inc.$388
  • Lilly USA, LLC$343
  • Xeris Pharmaceuticals, Inc.$192
  • AstraZeneca$190
  • Abbott$186
  • plus $659 from 10 others

What the payments were for

  • Food & beverage$2,29796%
  • Education$1034%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,400 in reported general payments places this provider in the 60th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$111,120
Medicare patients
228
Services billed
4,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide262$326,008
OzempicSemaglutide151$217,462
TrulicityDulaglutide125$154,244
JardianceEmpagliflozin66$79,722
FarxigaDapagliflozin Propanediol72$77,298
RybelsusSemaglutide40$74,034
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog76$62,873
Humalog Kwikpen U-200Insulin Lispro25$42,904
Teriparatide18$41,658
Fiasp FlextouchInsulin Aspart (Niacinamide)36$34,585
TymlosAbaloparatide12$31,156
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/741$31,075
Tresiba Flextouch U-100Insulin Degludec46$21,817
JanuviaSitagliptin Phosphate17$21,746
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog41$20,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$343$485,226409 claims
Novo NordiskOzempic, Rybelsus$441$291,496191 claims
Boehringer IngelheimJardiance$29$79,72266 claims
AstraZenecaFarxiga$190$77,29872 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$158$10,43115 claims
AbbVieSynthroid$18$2,00947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →